Commercial Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 4, 2026 BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Celcuity strengthens case for ASCO-spotlighted breast cancer drugNext: Part D Retail Prescription Drugs Related Stories Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026 Commercial Daiichi takes $850M charge, axes facility investment as ADC demand forecast falls pharminent May 11, 2026
